Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $7.00 million. The enterprise value is -$14.59 million.
Important Dates
The next estimated earnings date is Monday, May 19, 2025, after market close.
| Earnings Date | May 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 5.07 million shares outstanding. The number of shares has increased by 84.94% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | +84.94% |
| Shares Change (QoQ) | +220.26% |
| Owned by Insiders (%) | 7.23% |
| Owned by Institutions (%) | 11.14% |
| Float | 4.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.14 |
| Forward PS | 27.57 |
| PB Ratio | -0.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.16
| Current Ratio | 2.16 |
| Quick Ratio | 2.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -65.35% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -185.49% |
| Revenue Per Employee | $32,286 |
| Profits Per Employee | -$7.81M |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.39% in the last 52 weeks. The beta is 1.59, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -91.39% |
| 50-Day Moving Average | 2.11 |
| 200-Day Moving Average | 5.64 |
| Relative Strength Index (RSI) | 32.31 |
| Average Volume (20 Days) | 68,974 |
Short Selling Information
The latest short interest is 73,982, so 1.46% of the outstanding shares have been sold short.
| Short Interest | 73,982 |
| Short Previous Month | 76,884 |
| Short % of Shares Out | 1.46% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 1.25 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $226,000 and -$54.67 million in losses. Loss per share was -$35.21.
| Revenue | 226,000 |
| Gross Profit | 226,000 |
| Operating Income | -24.91M |
| Pretax Income | -18.16M |
| Net Income | -54.67M |
| EBITDA | -24.90M |
| EBIT | -24.91M |
| Loss Per Share | -$35.21 |
Full Income StatementBalance Sheet
The company has $21.34 million in cash and n/a in debt, giving a net cash position of $21.34 million or $4.21 per share.
| Cash & Cash Equivalents | 21.34M |
| Total Debt | n/a |
| Net Cash | 21.34M |
| Net Cash Per Share | $4.21 |
| Equity (Book Value) | -31.63M |
| Book Value Per Share | -8.66 |
| Working Capital | 13.42M |
Full Balance SheetCash Flow
| Operating Cash Flow | -29.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -29.79M |
| FCF Per Share | -$5.87 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -11,022.12% |
| Pretax Margin | -73,682.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |